Ana Sayfa
Piyasalar
Grafikler ve Fikirler
Algo
Haberler
Store
Aracı Kurumlar
İndir
Ekonomik Takvim
Alım-Satım Sinyalleri
Web Terminali
Heatmap
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
KRYS
#1037
Krystal Biotech, Inc. Common Stock
270.000
0
USD
+0.97%
Sektör:
Sağlık Hizmetleri
Baz:
USD
Kar Para Birimi:
USD
Günlük Aralık
Yıllık Aralık
Günlük Değişim
+0.97%
Aylık Değişim
+7.24%
6 aylık değişim
+44.28%
Yıllık Değişim
+44.28%
Önceki Kapanış
267.410
0
Open
270.000
0
Bid
Ask
Low
270.000
0
High
270.000
0
Hacim
52
Piyasalar
ABD Borsası
Sağlık Hizmetleri
KRYS
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
22.19 M
25.21 M
25.76 M
28.29 M
28.81 M
29.23 M
—
Valuation ratios
Enterprise value
1.06 B
1.42 B
1.88 B
3.18 B
4.17 B
6.71 B
19.96 B
Price to earnings ratio
—
-22.35
-14.43
320.41
52.22
36.04
133.59
Price to sales ratio
—
—
-28.05 K
68.4
16.04
18.98
60.59
Price to cash flow ratio
—
-32.39
-20.08
-39.05
37.75
36.76
126.42
Price to book ratio
—
2.62
3.87
4.45
4.92
6.05
9.87
Enterprise value to EBITDA ratio
-34.1
-21.71
-13.31
-29.97
58.16
40.18
136.91
Profitability ratios
Return on assets %
-0.1
-0.11
-0.25
0.01
0.08
0.15
0.17
Return on equity %
-0.11
-0.12
-0.27
0.01
0.09
0.17
0.19
Return on invested capital %
-411.43
-220.38
-293.7
-156.2
67.23
147.22
148.92
Gross margin %
100
—
100
100
100
100
400
Operating margin %
100 K
—
201.66 K
-216.43
22.61
41.45
165.75
EBITDA margin %
94.49 K
—
196.13 K
-209.07
24.67
42.92
171.64
Net margin %
97.48 K
—
194.41 K
21.56
30.69
52.64
209.57
Liquidity ratios
Quick ratio
—
—
—
17.55
7.02
9.56
37.88
Current ratio
17.8
17.18
13.3
17.76
7.28
9.95
39.42
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
-0
0
-0
0.07
0.31
0.33
0.34
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-2.16
-3.95
-3.2
4.15
6.71
6.73
EBIT per share
—
-3.08
-5.7
-3.95
2.21
5.39
5.4
EBITDA per share
—
-2.95
-5.54
-3.82
2.41
5.58
5.59
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
19.74
14.88
19.18
20.09
27.64
95.72
Net current asset value per share
—
19.92
15.06
21.18
24.95
34.21
119.19
Tangible book value per share
—
26.74
20.49
28.06
31.82
40.72
146.81
Working capital per share
—
18.77
13.92
19.99
21.52
30.77
107.11
Book value per share
—
26.74
20.49
28.06
31.82
40.72
146.81
Haberler
Palvella pazar erişim başkanlığına Jennifer McDonough’u atadı
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
Krystal Biotech başkanı 6,58 milyon dolarlık hisse sattı
Krishnan Krish S, president of Krystal Biotech, sells $6.58 million in KRYS stock
Krystal Biotech yöneticisi Krishnan 6,58 milyon dolarlık hisse sattı
Krystal Biotech director Krishnan sells $6.58 million in shares
Krystal Biotech TD Cowen Konferansı: Stratejik Büyüme ve Zorluklar
Krystal Biotech at TD Cowen Conference: Strategic Growth and Challenges
Daniel Janney, Krystal Biotech hisselerini 3,25 milyon dolara sattı